BACKGROUND: Sweat testing is a noninvasive technique for monitoring drug exposure in treatment, criminal justice, and employment settings. METHODS: We evaluated cocaine excretion in 9 participants' sweat after they received 3 low doses (75 mg/70 kg) of cocaine HCl subcutaneously within 1 week and, 3 weeks later, 3 high doses (150 mg/70 kg). Six additional participants completed portions of the study. PharmChek sweat patches (n = 1390) were collected throughout a 3-week washout period, reflecting previously self-administered drugs, and during and after controlled dosing. RESULTS: Cocaine was the primary analyte detected with 24% of patches positive at the gas chromatography-mass spectrometry limit of quantification of 2.5 ng/patch and 7% of patches at the proposed Substance Abuse and Mental Health Services Administration cutoff of 25 ng/patch. Ecgonine methyl ester (EME) was detected more often and at generally higher concentrations than benzoylecgonine. In patches containing both metabolites, there was no statistically significant difference in the benzoylecgonine/EME ratio based on length of patch wear. During washout, 2 participants' weekly patches tested positive (> or =25 ng/patch) during the first week; one remained positive during week 2; and none were positive during week 3. Cocaine and EME were detectable within 2 h; benzoylecgonine was not detected until 4-8 h after low doses and slightly sooner after high doses. The majority of drug was excreted within 24 h. Over 70% of weekly patches worn during low doses were positive for cocaine (> or =25 ng/patch), increasing to 100% during high doses. CONCLUSION: Sweat testing is an effective and reliable method of monitoring cocaine exposure.
BACKGROUND: Sweat testing is a noninvasive technique for monitoring drug exposure in treatment, criminal justice, and employment settings. METHODS: We evaluated cocaine excretion in 9 participants' sweat after they received 3 low doses (75 mg/70 kg) of cocaine HCl subcutaneously within 1 week and, 3 weeks later, 3 high doses (150 mg/70 kg). Six additional participants completed portions of the study. PharmChek sweat patches (n = 1390) were collected throughout a 3-week washout period, reflecting previously self-administered drugs, and during and after controlled dosing. RESULTS:Cocaine was the primary analyte detected with 24% of patches positive at the gas chromatography-mass spectrometry limit of quantification of 2.5 ng/patch and 7% of patches at the proposed Substance Abuse and Mental Health Services Administration cutoff of 25 ng/patch. Ecgonine methyl ester (EME) was detected more often and at generally higher concentrations than benzoylecgonine. In patches containing both metabolites, there was no statistically significant difference in the benzoylecgonine/EME ratio based on length of patch wear. During washout, 2 participants' weekly patches tested positive (> or =25 ng/patch) during the first week; one remained positive during week 2; and none were positive during week 3. Cocaine and EME were detectable within 2 h; benzoylecgonine was not detected until 4-8 h after low doses and slightly sooner after high doses. The majority of drug was excreted within 24 h. Over 70% of weekly patches worn during low doses were positive for cocaine (> or =25 ng/patch), increasing to 100% during high doses. CONCLUSION: Sweat testing is an effective and reliable method of monitoring cocaine exposure.
Authors: Michael L Smith; Shawn P Vorce; Justin M Holler; Eric Shimomura; Joe Magluilo; Aaron J Jacobs; Marilyn A Huestis Journal: J Anal Toxicol Date: 2007-06 Impact factor: 3.367
Authors: Allan J Barnes; Bertrand R Brunet; Robin E Choo; Patrick Mura; Rolley E Johnson; Hendrée E Jones; Marilyn A Huestis Journal: Ther Drug Monit Date: 2010-08 Impact factor: 3.681
Authors: Karl B Scheidweiler; Erin A Kolbrich Spargo; Tamsin L Kelly; Edward J Cone; Allan J Barnes; Marilyn A Huestis Journal: Ther Drug Monit Date: 2010-10 Impact factor: 3.681
Authors: Allan J Barnes; Michael L Smith; Sherri L Kacinko; Eugene W Schwilke; Edward J Cone; Eric T Moolchan; Marilyn A Huestis Journal: Clin Chem Date: 2007-11-02 Impact factor: 8.327
Authors: Marilyn A Huestis; Karl B Scheidweiler; Takeshi Saito; Neil Fortner; Tsadik Abraham; Richard A Gustafson; Michael L Smith Journal: Forensic Sci Int Date: 2007-05-03 Impact factor: 2.395
Authors: Bertrand R Brunet; Allan J Barnes; Robin E Choo; Patrick Mura; Hendre E E Jones; Marilyn A Huestis Journal: Ther Drug Monit Date: 2010-02 Impact factor: 3.681
Authors: Bertrand R Brunet; Allan J Barnes; Karl B Scheidweiler; Patrick Mura; Marilyn A Huestis Journal: Anal Bioanal Chem Date: 2008-07-08 Impact factor: 4.142